iScience (Jan 2023)
An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
- Alexandre Nicolas,
- Gérémy Sannier,
- Mathieu Dubé,
- Manon Nayrac,
- Alexandra Tauzin,
- Mark M. Painter,
- Rishi R. Goel,
- Mélanie Laporte,
- Gabrielle Gendron-Lepage,
- Halima Medjahed,
- Justine C. Williams,
- Nathalie Brassard,
- Julia Niessl,
- Laurie Gokool,
- Chantal Morrisseau,
- Pascale Arlotto,
- Cécile Tremblay,
- Valérie Martel-Laferrière,
- Andrés Finzi,
- Allison R. Greenplate,
- E. John Wherry,
- Daniel E. Kaufmann
Affiliations
- Alexandre Nicolas
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Gérémy Sannier
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Mathieu Dubé
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Manon Nayrac
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Alexandra Tauzin
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Mark M. Painter
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health®, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
- Rishi R. Goel
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health®, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
- Mélanie Laporte
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Gabrielle Gendron-Lepage
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Halima Medjahed
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Justine C. Williams
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
- Nathalie Brassard
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Julia Niessl
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Laurie Gokool
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Chantal Morrisseau
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Pascale Arlotto
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada
- Cécile Tremblay
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Valérie Martel-Laferrière
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Andrés Finzi
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC H2X 0A9, Canada
- Allison R. Greenplate
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health®, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
- E. John Wherry
- Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health®, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
- Daniel E. Kaufmann
- Centre de Recherche du CHUM, Montréal, QC H2X 0A9 Canada; Département de Médecine, Université de Montréal, Montréal, QC H3T 1J4, Canada; Division of Infectious Diseases, Department of Medicine, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland; Corresponding author
- Journal volume & issue
-
Vol. 26,
no. 1
p. 105904
Abstract
Summary: Spacing the first two doses of SARS-CoV-2 mRNA vaccines beyond 3–4 weeks raised initial concerns about vaccine efficacy. While studies have since shown that long-interval regimens induce robust antibody responses, their impact on B and T cell immunity is poorly known. Here, we compare SARS-CoV-2 naive donors B and T cell responses to two mRNA vaccine doses administered 3–4 versus 16 weeks apart. After boost, the longer interval results in a higher magnitude and a more mature phenotype of RBD-specific B cells. While the two geographically distinct cohorts present quantitative and qualitative differences in T cell responses at baseline and after priming, the second dose led to convergent features with overall similar magnitude, phenotype, and function of CD4+ and CD8+ T cell responses at post-boost memory time points. Therefore, compared to standard regimens, a 16-week interval has a favorable impact on the B cell compartment but minimally affects T cell immunity.
